サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1595029

希少バイオマーカー検体の収集と安定化の世界市場

Rare Biomarkers Specimen Collection and Stabilization

出版日
ページ情報
英文 88 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
希少バイオマーカー検体の収集と安定化の世界市場
出版日: 2024年11月22日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 88 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

希少バイオマーカー検体の収集と安定化の世界市場は2030年までに878億米ドルに到達

2023年に474億米ドルと推定される希少バイオマーカー検体の収集と安定化の世界市場は、分析期間2023-2030年にCAGR 9.2%で成長し、2030年には878億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである循環遊離細胞DNA（ccfDNA）は、CAGR 8.5％を記録し、分析期間終了までに340億米ドルに達すると予測されます。循環腫瘍細胞（CTC）セグメントの成長率は、分析期間中CAGR 9.7%と推定されます。

米国市場は131億米ドルと推定、中国はCAGR 8.5%で成長予測

米国の希少バイオマーカー検体の収集と安定化市場は2023年に131億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに133億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは8.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.4%と7.6%と予測されています。欧州では、ドイツがCAGR約7.6％で成長すると予測されています。

希少バイオマーカー検体の収集と安定化：バイオメディカル研究における精度の向上

希少バイオマーカーとは何か、なぜ検体の収集と安定化が重要なのか？

希少バイオマーカーとは、体内の限られた濃度に存在する特定の生物学的分子のことで、血液、尿、組織サンプルに多く含まれ、特定の病状、治療に対する反応、遺伝的プロファイルを示します。これらのバイオマーカーは、がん、遺伝性疾患、神経変性疾患など様々な疾患の診断、モニタリング、予後予測に不可欠です。希少バイオマーカーを検出することで、疾患の早期発見、標的治療、個別化医療へのアプローチが可能になります。しかし、バイオマーカーの存在量が少ないため、同定や測定が困難であり、特に検体採取後に分解したり、急速に変化したりする可能性があります。従って、これらのバイオマーカーの完全性と信頼性を維持し、正確な分析を行うためには、適切な検体の採取と安定化が不可欠です。

希少バイオマーカーの効果的な収集と安定化により、バイオマーカーがサンプリングされた瞬間から分析されるまで変化しないことが保証されます。このプロセスでは、バイオマーカーの劣化を防ぐために、収集器具を慎重に選択し、安定化剤を使用し、厳格なプロトコールに従います。不適切な取り扱いは、不正確な検査結果、病態の誤った解釈、診断の見落としにつながる可能性があり、精密医療と研究における安定性の重要性を浮き彫りにしています。希少バイオマーカーが極めて重要な役割を果たすことが多い個別化医療が重視されるようになり、検体の採取と安定化処理は、診断精度を向上させ、高度なバイオマーカー研究を可能にするための焦点となっています。

希少バイオマーカーの検体収集と安定化にはどのような方法が用いられるのか？

希少バイオマーカーを含む検体の収集と安定化には、その構造と機能を維持するための特殊な技術が必要です。血液ベースのバイオマーカーは、凝固を防ぎ、細胞を含まないDNA、RNA、タンパク質を保存するEDTAやヘパリンなどの抗凝固剤や安定化剤を含む特殊なチューブで収集されることがよくあります。例えば、循環腫瘍DNA（ctDNA）のような希少なバイオマーカーの場合、独自の安定化剤を使用した採血管は、細胞の分解を防ぎ、核酸の完全性を数日間維持するのに役立ち、より正確なダウンストリーム分析を可能にします。血漿と血清の分離もまた、安定化プロセスにおいて不可欠なステップです。

尿や唾液のサンプルの場合、感度の高いバイオマーカーの分解を防ぐために、直ちに冷却するか、保存剤を添加する必要があります。組織検体やその他の生物学的検体には、タンパク質や核酸を保存するために、液体窒素中で検体を即座に凍結するスナップフリージングが一般的に使用されます。また、RNAやタンパク質ベースのバイオマーカーには、急速な分解を防ぐために安定化バッファーが使用されます。さらに、マイクロ流体工学とバイオ保存技術の進歩により、希少バイオマーカーの室温保存が可能になり、検体の取り扱いと輸送が容易になりました。各サンプルがバイオマーカーの種類に応じた特定の要件に従って慎重に処理・保存されるようにすることで、サンプルの完全性が維持され、研究者はバイオマーカー研究で信頼性と再現性の高いデータを得ることができます。

技術の進歩は希少バイオマーカーの収集と安定化をどのように改善しているか？

技術革新は希少バイオマーカーの収集と安定化を進め、より高い感度、精度、保存を可能にしています。マイクロ流体デバイスは、非常に少量のサンプルの収集と分析を可能にし、希少バイオマーカーを保存し、劣化リスクを最小限に抑えます。これらの装置では、サンプルから直接バイオマーカーを分離・濃縮できるため、大規模な処理が不要になり、バイオマーカー分離の効率が向上します。さらに、安定化剤は室温でもバイオマーカーの安定性を長期間維持できるように配合されています。これにより、コールドチェーンロジスティクスへの依存が軽減され、特に遠隔地やフィールドベースの検体採取において、検体の取り扱いと保管が簡素化されます。

デジタルPCR（dPCR）と次世代シーケンサー（NGS）はまた、超高感度検出機能を提供することにより、希少バイオマーカー分析を一変させ、研究者は極めて低濃度で存在するバイオマーカーの検出と定量を可能にしました。さらに、バイオセンサーベースの収集装置が開発され、収集と同時に希少バイオマーカーを検出できるようになり、大規模な安定化や輸送プロセスの必要性がなくなった。自動化とロボットシステムも検体の収集と取り扱いを強化し、安定化プロトコルが正確に守られるようにしながら、人為的ミスや汚染のリスクを減らしています。これらの技術は、強固なバイオマーカーの収集と保存を可能にし、より正確な診断ツールや個別化治療の開発を促進する上で極めて重要です。

何が希少バイオマーカー検体の収集と安定化市場の成長を促進しているのか？

希少バイオマーカー検体の収集と安定化市場の成長は、精密医療への需要の高まり、診断技術の進歩、早期発見を必要とする複雑な疾患の増加によってもたらされます。ヘルスケア産業が個別化治療へとシフトする中、特にがんや神経疾患などの疾患では、標的治療の指針となる信頼性の高いバイオマーカーの必要性が急増しています。研究者や臨床医は、情報に基づいた意思決定を行うために正確で安定したバイオマーカーデータに依存しており、この需要に応えるためには高品質の検体収集と安定化ツールへの投資が不可欠です。

さらに、バイオマーカーに基づく診断に対する規制要件や基準は、特にコンパニオン診断やバイオマーカー主導型治療が普及するにつれて厳しくなっています。標準化された収集・安定化プロトコルの必要性から、ヘルスケアプロバイダー、研究機関、診断薬企業は、データの正確性と再現性を確保する先進的なソリューションの採用を促しています。新たなバイオマーカーを同定するための研究開発への投資が増加していることも、希少バイオマーカーの保存をサポートする技術への需要を後押ししています。これらの要因が一体となって成長を牽引しているため、希少バイオマーカー検体の収集・安定化市場は拡大し、診断の精度向上と個別化医療におけるブレークスルーへの道を開くことになります。

セグメント

製品タイプ（循環遊離DNA（ccfDNA）、循環腫瘍細胞（CTC）、エクソソーム／細胞外小胞、循環遊離RNA（ccfRNA）／miRNA）;エンドユーズ（調査、診断薬）

調査対象企業の例（注目の全32社）

  • Advanced Cell Diagnostics, Inc.
  • Agena Bioscience
  • ANGLE plc
  • ApoCell, Inc.
  • AS One InternationalNTERNATIONAL
  • BioChain Institute, Inc.
  • Biolidics Limited
  • Biomatrica
  • Bio-Techne Corporation
  • BioVision, Inc.
  • Caltag Medsystems Limited
  • Cytomark Ltd.
  • DNA Genotek, Inc.
  • Epic Sciences
  • EpiGentek Group Inc.
  • F. Hoffmann-La Roche Ltd
  • Fluxion Biosciences, Inc.
  • Geno Technology Inc.
  • Genomax Technologies Pte Ltd.
  • GILUPI GmbH
  • LifeSpan BioSciences, Inc.
  • MagBio Genomics Inc.
  • Menarini Silicon Biosystems
  • MyBioSource.com
  • Norgen Biotek Corp.
  • Novus Biologicals, LLC
  • OraSure Technologies Inc.
  • Precision for Medicine, Inc.
  • Promega Corporation
  • QIAGEN
  • Rarecells Diagnostics SAS
  • RareCyte, Inc.
  • siemens Healthineers
  • SiO2 Materials Science
  • STEMCELL Technologies Inc.
  • Streck, Inc.
  • Thermo Fisher Scientific, Inc.
  • Vortex Biosciences
  • VyCAP B.V.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP22681

Global Rare Biomarkers Specimen Collection and Stabilization Market to Reach US$87.8 Billion by 2030

The global market for Rare Biomarkers Specimen Collection and Stabilization estimated at US$47.4 Billion in the year 2023, is expected to reach US$87.8 Billion by 2030, growing at a CAGR of 9.2% over the analysis period 2023-2030. Circulating Cell Free DNA (ccfDNA), one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$34.0 Billion by the end of the analysis period. Growth in the Circulating Tumor Cells (CTCs) segment is estimated at 9.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.1 Billion While China is Forecast to Grow at 8.5% CAGR

The Rare Biomarkers Specimen Collection and Stabilization market in the U.S. is estimated at US$13.1 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$13.3 Billion by the year 2030 trailing a CAGR of 8.5% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.4% and 7.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.

Rare Biomarkers Specimen Collection and Stabilization: Advancing Precision in Biomedical Research

What Are Rare Biomarkers, and Why Is Specimen Collection and Stabilization Important?

Rare biomarkers are specific biological molecules found in limited concentrations in the body, often present in blood, urine, or tissue samples, that indicate a particular disease state, response to treatment, or genetic profile. These biomarkers are essential in the diagnosis, monitoring, and prognosis of various conditions, including cancer, genetic disorders, and neurodegenerative diseases. Detecting rare biomarkers can enable early disease detection, targeted therapies, and personalized medicine approaches. However, their low abundance makes them challenging to identify and measure, especially as they may degrade or change rapidly after specimen collection. Thus, proper specimen collection and stabilization are critical to preserving the integrity and reliability of these biomarkers for accurate analysis.

Effective collection and stabilization of rare biomarkers ensure that they remain unchanged from the moment they are sampled until they are analyzed. This process involves carefully selecting collection devices, using stabilizing agents, and following stringent protocols to prevent biomarker degradation. Improper handling can lead to inaccurate test results, misinterpretation of a disease state, or missed diagnosis, underscoring the importance of stability in precision medicine and research. The growing emphasis on personalized medicine, where rare biomarkers often play a pivotal role, has made collection and stabilization practices a focal point for improving diagnostic accuracy and enabling advanced biomarker research.

What Methods Are Used for Specimen Collection and Stabilization of Rare Biomarkers?

Collecting and stabilizing specimens containing rare biomarkers requires specialized techniques to preserve their structure and functionality. Blood-based biomarkers are frequently collected in specialized tubes containing anticoagulants and stabilizing agents, such as EDTA or heparin, which prevent coagulation and preserve cell-free DNA, RNA, and proteins. For example, for rare biomarkers like circulating tumor DNA (ctDNA), blood collection tubes with proprietary stabilization agents help prevent cellular degradation and maintain nucleic acid integrity for several days, allowing for more accurate downstream analysis. Plasma and serum separation are also essential steps in the stabilization process, as these fluids contain critical biomarker information once separated from whole blood.

For urine and saliva samples, immediate cooling or addition of preservatives is often required to prevent the breakdown of sensitive biomarkers. Snap freezing—immediately freezing specimens in liquid nitrogen—is commonly used for tissue samples and other biological specimens to preserve proteins and nucleic acids. Stabilization buffers are also used for RNA and protein-based biomarkers to prevent rapid degradation. Moreover, advancements in microfluidics and biopreservation technologies enable the preservation of rare biomarkers at room temperature, making specimen handling and transport easier. Ensuring that each sample is carefully processed and stored according to specific requirements for each biomarker type helps maintain sample integrity, allowing researchers to obtain reliable and reproducible data in biomarker studies.

How Are Technological Advancements Improving Rare Biomarker Collection and Stabilization?

Technological innovations are advancing the collection and stabilization of rare biomarkers, enabling higher sensitivity, accuracy, and preservation. Microfluidic devices allow for the collection and analysis of very small sample volumes, preserving rare biomarkers and minimizing degradation risks. These devices can separate and concentrate biomarkers directly from the sample, eliminating the need for extensive processing and improving efficiency in biomarker isolation. Additionally, stabilizing agents have been formulated to maintain biomarker stability for longer periods, even at room temperature. This reduces the dependency on cold chain logistics and simplifies sample handling and storage, particularly for remote and field-based specimen collection.

Digital PCR (dPCR) and next-generation sequencing (NGS) have also transformed rare biomarker analysis by providing ultra-sensitive detection capabilities, allowing researchers to detect and quantify biomarkers that are present in extremely low concentrations. Furthermore, biosensor-based collection devices are being developed to detect rare biomarkers immediately upon collection, bypassing the need for extensive stabilization and transport processes. Automation and robotic systems are also enhancing specimen collection and handling, reducing the risk of human error and contamination while ensuring that stabilization protocols are followed with precision. These technologies are pivotal in enabling robust biomarker collection and preservation, facilitating the development of more accurate diagnostic tools and personalized treatments.

What Is Driving the Growth in the Rare Biomarker Specimen Collection and Stabilization Market?

The growth in the rare biomarker specimen collection and stabilization market is driven by the increasing demand for precision medicine, advancements in diagnostic technologies, and the rise in complex diseases requiring early detection. As the healthcare industry shifts toward individualized treatment, the need for reliable biomarkers to guide targeted therapies has surged, especially for diseases like cancer and neurological disorders. Researchers and clinicians rely on accurate and stable biomarker data to make informed decisions, and investments in high-quality specimen collection and stabilization tools are essential to meet this demand.

In addition, regulatory requirements and standards for biomarker-based diagnostics are becoming more stringent, especially as companion diagnostics and biomarker-driven therapies gain traction. The need for standardized collection and stabilization protocols is prompting healthcare providers, research institutions, and diagnostic companies to adopt advanced solutions that ensure data accuracy and reproducibility. Growing investment in research and development to identify new biomarkers has also fueled demand for technologies that support rare biomarker preservation. With these factors collectively driving growth, the market for rare biomarker specimen collection and stabilization is poised to expand, paving the way for breakthroughs in diagnostic precision and personalized medicine.

SCOPE OF STUDY:

The report analyzes the Rare Biomarkers Specimen Collection and Stabilization market in terms of US$ Million by the following End-Use; Product Type, and Geographic Regions/Countries:

Segments:

Product Type (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles, Circulating Cell Free RNA (ccfRNA) / miRNA); End-Use (Research, Diagnostics)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 32 Featured) -

  • Advanced Cell Diagnostics, Inc.
  • Agena Bioscience
  • ANGLE plc
  • ApoCell, Inc.
  • AS One InternationalNTERNATIONAL
  • BioChain Institute, Inc.
  • Biolidics Limited
  • Biomatrica
  • Bio-Techne Corporation
  • BioVision, Inc.
  • Caltag Medsystems Limited
  • Cytomark Ltd.
  • DNA Genotek, Inc.
  • Epic Sciences
  • EpiGentek Group Inc.
  • F. Hoffmann-La Roche Ltd
  • Fluxion Biosciences, Inc.
  • Geno Technology Inc.
  • Genomax Technologies Pte Ltd.
  • GILUPI GmbH
  • LifeSpan BioSciences, Inc.
  • MagBio Genomics Inc.
  • Menarini Silicon Biosystems
  • MyBioSource.com
  • Norgen Biotek Corp.
  • Novus Biologicals, LLC
  • OraSure Technologies Inc.
  • Precision for Medicine, Inc.
  • Promega Corporation
  • QIAGEN
  • Rarecells Diagnostics SAS
  • RareCyte, Inc.
  • siemens Healthineers
  • SiO2 Materials Science
  • STEMCELL Technologies Inc.
  • Streck, Inc.
  • Thermo Fisher Scientific, Inc.
  • Vortex Biosciences
  • VyCAP B.V.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Rare Biomarkers Specimen Collection and Stabilization - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Demand for Precision Medicine Drives Growth in Rare Biomarkers Specimen Collection and Stabilization
    • Rising Prevalence of Chronic and Complex Diseases Spurs Demand for Rare Biomarkers in Early Diagnosis
    • Advancements in Genomics and Proteomics Expand Applications of Rare Biomarker Specimen Collection
    • Growing Focus on Personalized Therapy Boosts Demand for Reliable Collection and Stabilization of Rare Biomarkers
    • Technological Innovations in Sample Preservation Techniques Enhance Quality and Viability of Rare Biomarker Specimens
    • Increasing Adoption of Liquid Biopsy Fuels Market for Non-Invasive Rare Biomarker Collection and Stabilization
    • Expansion of Biobanking and Long-Term Specimen Storage Drives Demand for Stable Rare Biomarker Samples
    • Rising Interest in Multi-Omics Research Spurs Demand for Rare Biomarker Collection in Proteomics and Metabolomics
    • Growing Applications of Rare Biomarkers in Cancer Diagnostics Drive Need for High-Integrity Collection Solutions
    • Collaboration Between Biotech Firms and Healthcare Institutions Fosters Innovation in Rare Biomarker Collection
    • Increasing Awareness of Biomarker Variability and Stability Enhances Demand for Reliable Collection Protocols
    • Expansion of Telemedicine and Remote Diagnostics Creates Opportunities for At-Home Specimen Collection Kits
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 3: World Recent Past, Current & Future Analysis for Circulating Cell Free DNA (ccfDNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 4: World 7-Year Perspective for Circulating Cell Free DNA (ccfDNA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World 7-Year Perspective for Circulating Tumor Cells (CTCs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Exosomes / Extracellular Vesicles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World 7-Year Perspective for Exosomes / Extracellular Vesicles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 9: World Recent Past, Current & Future Analysis for Circulating Cell Free RNA (ccfRNA) / miRNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 10: World 7-Year Perspective for Circulating Cell Free RNA (ccfRNA) / miRNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World 7-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World 7-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 15: World Rare Biomarkers Specimen Collection and Stabilization Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 16: USA Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 17: USA 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
    • TABLE 18: USA Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 19: USA 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
    • TABLE 22: Canada Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 23: Canada 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
  • JAPAN
    • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 24: Japan Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Japan 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
    • TABLE 26: Japan Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Japan 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
  • CHINA
    • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 28: China Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 29: China 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
    • TABLE 30: China Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 31: China 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
  • EUROPE
    • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
    • TABLE 36: Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
  • FRANCE
    • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 38: France Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: France 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
    • TABLE 40: France Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 41: France 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
  • GERMANY
    • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 42: Germany Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 43: Germany 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
    • TABLE 44: Germany Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Germany 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
  • ITALY
    • TABLE 46: Italy Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Italy 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
    • TABLE 48: Italy Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Italy 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
  • UNITED KINGDOM
    • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 50: UK Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: UK 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
    • TABLE 52: UK Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 53: UK 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 55: Rest of Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
    • TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Rest of Europe 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Asia-Pacific 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
    • TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Asia-Pacific 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 62: Rest of World Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Rest of World 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2024 & 2030
    • TABLE 64: Rest of World Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Rest of World 7-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2024 & 2030

IV. COMPETITION